Skip to main content
AAN.com
Articles
March 7, 2011

Subthalamic nucleus deep brain stimulation in primary cervical dystonia

March 8, 2011 issue
76 (10) 870-878

Abstract

Objectives:

The globus pallidus internus (GPi) has been the primary target for deep brain stimulation (DBS) to treat severe medication-refractory dystonia. Some patients with primary cervical or segmental dystonia develop subtle bradykinesia occurring in previously nondystonic body regions during GPi DBS. Subthalamic nucleus (STN) DBS may provide an alternative target choice for treating dystonia, but has only been described in a few short reports, without blinded rating scales, statistical analysis, or detailed neuropsychological studies.

Methods:

In this prospective pilot study, we analyzed the effect of bilateral STN DBS on safety, efficacy, quality of life, and neuropsychological functioning in 9 patients with medically refractory primary cervical dystonia. Severity of dystonia was scored by a blinded rater (unaware of the patient's preoperative or postoperative status) using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) preoperatively and 3, 6, and 12 months postsurgery. Lead location, medications, and adverse events were also measured.

Results:

STN DBS was well-tolerated with no serious adverse effects. The TWSTRS total score improved (p < 0.001) from a mean (±SEM) of 53.1 (±2.57), to 19.6 (±5.48) at 12 months. Quality of life measures were also improved. STN DBS induced no consistent neuropsychological deficits. Several patients reported depression in the study and 3 had marked weight gain. No patients developed bradykinetic side effects from stimulation, but all patients developed transient dyskinetic movements during stimulation.

Conclusions:

This prospective study showed that bilateral STN DBS resulted in improvement in dystonia and suggests that STN DBS may be an alternative to GPi DBS for treating primary cervical dystonia.

Classification of evidence:

This study provides Class III evidence that bilateral subthalamic nucleus deep brain stimulation results in significant improvement in cervical dystonia without bradykinetic side effects.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (table_e-1.doc)
File (table_e-2.doc)
File (table_e-3.doc)

REFERENCES

1.
Vidailhet M, Vercueil L, Houeto JL, et al. Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med 2005;352:459–467.
2.
Kupsch A, Benecke R, Muller J, et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med 2006;355:1978–1990.
3.
Coubes P, Cif L, El Fertit H, et al. Electrical stimulation of the globus pallidus internus in patients with primary generalized dystonia: long-term results. J Neurosurg 2004;101:189–194.
4.
Hung SW, Hamani C, Lozano AM, et al. Long-term outcome of bilateral pallidal deep brain stimulation for primary cervical dystonia. Neurology 2007;68:457–459.
5.
Kiss ZH, Doig-Beyaert K, Eliasziw M, Tsui J, Haffenden A, Suchowersky O. The Canadian multicentre study of deep brain stimulation for cervical dystonia. Brain 2007;130:2879–2886.
6.
Ostrem JL, Marks WJ, Volz MM, Heath SL, Starr PA. Pallidal deep brain stimulation in patients with cranial-cervical dystonia (Meige syndrome). Mov Disord 2007;22:1885–1891.
7.
Hubl J, Kupsch A, Kuhn AA. Frequency-specific effects of deep brain stimulation on hand function in patients with cervical dystonia. Mov Disord 2009;24:Tu-58. Abstract.
8.
Zauber SE, Watson N, Comella CL, Bakay RA, Verhagen Metman L. Stimulation-induced parkinsonism after posteroventral deep brain stimulation of the globus pallidus internus for craniocervical dystonia. J Neurosurg 2009;110:229–233.
9.
Berman BD, Starr PA, Marks WJ, Ostrem JL. Induction of bradykinesia with pallidal deep brain stimulation in patients with cranial-cervical dystonia. Stereotact Funct Neurosurg 2009;87:37–44.
10.
Tisch S, Zrinzo L, Limousin P, et al. Effect of electrode contact location on clinical efficacy of pallidal deep brain stimulation in primary generalised dystonia. J Neurol Neurosurg Psychiatry 2007;78:1314–1319.
11.
Sun B, Chen S, Zhan S, Le W, Krahl SE. Subthalamic nucleus stimulation for primary dystonia and tardive dystonia. Acta Neurochir Suppl 2007;97:207–214.
12.
Kleiner-Fisman G, Liang GS, Moberg PJ, et al. Subthalamic nucleus deep brain stimulation for severe idiopathic dystonia: impact on severity, neuropsychological status, and quality of life. J Neurosurg 2007;107:29–36.
13.
Starr PA, Christine CW, Theodosopoulos PV, et al. Implantation of deep brain stimulators into the subthalamic nucleus: technical approach and magnetic resonance imaging-verified lead locations. J Neurosurg 2002;97:370–387.
14.
Schrock LE, Ostrem JL, Turner RS, Shimamoto SA, Starr PA. The subthalamic nucleus in primary dystonia: single-unit discharge characteristics. J Neurophysiol 2009;102:3740–3752.
15.
Fabbrini G, Berardelli I, Moretti G, et al. Psychiatric disorders in adult-onset focal dystonia: a case-control study. Mov Disord 2010;25:459–465.
16.
Scott RB, Gregory R, Wilson J, et al. Executive cognitive deficits in primary dystonia. Mov Disord 2003;18:539–550.
17.
Wenzel T, Schnider P, Wimmer A, Steinhoff N, Moraru E, Auff E. Psychiatric comorbidity in patients with spasmodic torticollis. J Psychosom Res 1998;44:687–690.
18.
Mallet L, Polosan M, Jaafari N, et al. Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med 2008;359:2121–2134.
19.
Chabardes S, Kahane P, Minotti L, Koudsie A, Hirsch E, Benabid AL. Deep brain stimulation in epilepsy with particular reference to the subthalamic nucleus. Epileptic Disord 2002;4(suppl 3):S83–S93.
20.
Hazrati LN, Parent A. Differential patterns of arborization of striatal and subthalamic fibers in the two pallidal segments in primates. Brain Res 1992;598:311–315.
21.
Mink JW. The basal ganglia: focused selection and inhibition of competing motor programs. Prog Neurobiol 1996;50:381–425.
22.
Krack P, Pollak P, Limousin P, et al. Opposite motor effects of pallidal stimulation in Parkinson's disease. Ann Neurol 1998;43:180–192.
23.
Isaias IU, Alterman RL, Tagliati M. Outcome predictors of pallidal stimulation in patients with primary dystonia: the role of disease duration. Brain 2008;131:1895–1902.
24.
Parsons TD, Rogers SA, Braaten AJ, Woods SP, Troster AI. Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis. Lancet Neurol 2006;5:578–588.
25.
Alberts JL, Voelcker-Rehage C, Hallahan K, Vitek M, Bamzai R, Vitek JL. Bilateral subthalamic stimulation impairs cognitive-motor performance in Parkinson's disease patients. Brain 2008;131:3348–3360.
26.
Montaurier C, Morio B, Bannier S, et al. Mechanisms of body weight gain in patients with Parkinson's disease after subthalamic stimulation. Brain 2007;130:1808–1818.
27.
Tang JK, Moro E, Mahant N, et al. Neuronal firing rates and patterns in the globus pallidus internus of patients with cervical dystonia differ from those with Parkinson's disease. J Neurophysiol 2007;98:720–729.
28.
Merello M, Cerquetti D, Cammarota A, et al. Neuronal globus pallidus activity in patients with generalised dystonia. Mov Disord 2004;19:548–554.
29.
Vitek JL, Chockkan V, Zhang JY, et al. Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus. Ann Neurol 1999;46:22–35.
30.
Starr PA, Rau GM, Davis V, et al. Spontaneous pallidal neuronal activity in human dystonia: comparison with Parkinson's disease and normal macaque. J Neurophysiol 2005;93:3165–3176.

Information & Authors

Information

Published In

Neurology®
Volume 76Number 10March 8, 2011
Pages: 870-878
PubMed: 21383323

Publication History

Received: August 19, 2010
Accepted: November 18, 2010
Published online: March 7, 2011
Published in print: March 8, 2011

Permissions

Request permissions for this article.

Disclosure

Dr. Ostrem serves on the speakers' bureau for and has received funding for travel and speaker honoraria from Allergan, Inc.; serves as a consultant for Boston Scientific; performs clinical examinations (80% effort) for the UCSF Surgical Movement Disorders Center; and receives research support from Ceregene, St. Jude Medical, Inc., SurgiVision, Inc., Allergan, Inc., the NIH, UC Discovery Grant, and the Benign Essential Blepharospasm Research Foundation. Dr. Racine has served as a consultant for Novartis and has received/receives research support from Novartis, UC Discovery Grant Award, UCSF Brain Tumor SPORE Developmental Award, private donors, and the Anonymous Foundation. Dr. Glass serves on the speakers' bureau for and has received funding for travel and speaker honoraria from Allergan, Inc. J.K. Grace reports no disclosures. M.M. Volz serves as a consultant and on the speakers' bureau for and has received funding for travel and speaker honoraria from Medtronic, Inc.; employs SurgiVision imaging technology (25% effort) in the UCSF Surgical Movement Disorders Practice; and receives research support from SurgiVision, Inc. and the Benign Essential Blepharospasm Research Foundation. S.L. Heath serves as a consultant and on the speakers' bureau for and has received funding for travel and speaker honoraria from Medtronic, Inc. Dr. Starr serves on a scientific advisory board for Protein Therapeutics, Inc.; serves on the editorial board of Stereotactic and Functional Neurosurgery; serves as a consultant for Boston Scientific; and receives research support from SurgiVision, Inc. the NIH, and the Dystonia Medical Research Foundation.

Authors

Affiliations & Disclosures

J.L. Ostrem, MD
From the Departments of Neurology (J.L.O., G.A.G., J.K.G., M.M.V.) and Neurological Surgery (C.A.R., P.A.S.), University of California, San Francisco, Surgical Movement Disorders, San Francisco; and Parkinson's Disease Research, Education, and Clinical Center (J.L.O., G.A.G., S.L.H., P.A.S.), San Francisco Veterans Affairs Medical Center, San Francisco, CA.
C.A. Racine, PhD
From the Departments of Neurology (J.L.O., G.A.G., J.K.G., M.M.V.) and Neurological Surgery (C.A.R., P.A.S.), University of California, San Francisco, Surgical Movement Disorders, San Francisco; and Parkinson's Disease Research, Education, and Clinical Center (J.L.O., G.A.G., S.L.H., P.A.S.), San Francisco Veterans Affairs Medical Center, San Francisco, CA.
G.A. Glass, MD
From the Departments of Neurology (J.L.O., G.A.G., J.K.G., M.M.V.) and Neurological Surgery (C.A.R., P.A.S.), University of California, San Francisco, Surgical Movement Disorders, San Francisco; and Parkinson's Disease Research, Education, and Clinical Center (J.L.O., G.A.G., S.L.H., P.A.S.), San Francisco Veterans Affairs Medical Center, San Francisco, CA.
J.K. Grace, BS
From the Departments of Neurology (J.L.O., G.A.G., J.K.G., M.M.V.) and Neurological Surgery (C.A.R., P.A.S.), University of California, San Francisco, Surgical Movement Disorders, San Francisco; and Parkinson's Disease Research, Education, and Clinical Center (J.L.O., G.A.G., S.L.H., P.A.S.), San Francisco Veterans Affairs Medical Center, San Francisco, CA.
M.M. Volz, MS, RN
From the Departments of Neurology (J.L.O., G.A.G., J.K.G., M.M.V.) and Neurological Surgery (C.A.R., P.A.S.), University of California, San Francisco, Surgical Movement Disorders, San Francisco; and Parkinson's Disease Research, Education, and Clinical Center (J.L.O., G.A.G., S.L.H., P.A.S.), San Francisco Veterans Affairs Medical Center, San Francisco, CA.
S.L. Heath, MS, RN
From the Departments of Neurology (J.L.O., G.A.G., J.K.G., M.M.V.) and Neurological Surgery (C.A.R., P.A.S.), University of California, San Francisco, Surgical Movement Disorders, San Francisco; and Parkinson's Disease Research, Education, and Clinical Center (J.L.O., G.A.G., S.L.H., P.A.S.), San Francisco Veterans Affairs Medical Center, San Francisco, CA.
P.A. Starr, MD, PhD
From the Departments of Neurology (J.L.O., G.A.G., J.K.G., M.M.V.) and Neurological Surgery (C.A.R., P.A.S.), University of California, San Francisco, Surgical Movement Disorders, San Francisco; and Parkinson's Disease Research, Education, and Clinical Center (J.L.O., G.A.G., S.L.H., P.A.S.), San Francisco Veterans Affairs Medical Center, San Francisco, CA.

Notes

Address correspondence and reprint requests to Dr. Jill L. Ostrem, Department of Neurology, Surgical Movement Disorders, 1635 Divisadero Street, Fifth Floor, Suites 520–530, San Francisco, CA 94115 [email protected]
Study funding: Supported by the Benign Essential Blepharospasm Research Foundation and by private donors Larry and Kana Miao.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Engaging dystonia networks with subthalamic stimulation, Proceedings of the National Academy of Sciences, 122, 2, (2025).https://doi.org/10.1073/pnas.2417617122
    Crossref
  2. Deep brain stimulation, Encyclopedia of the Human Brain, (16-41), (2025).https://doi.org/10.1016/B978-0-12-820480-1.00212-6
    Crossref
  3. Sustained quality-of-life improvements over 10 years after subthalamic nucleus deep brain stimulation for isolated dystonia, Journal of Neurology, 272, 1, (2025).https://doi.org/10.1007/s00415-024-12820-4
    Crossref
  4. Alternative Deep Brain Stimulation Targets in the Treatment of Isolated Dystonic Syndromes: A Multicenter Experience‐Based Survey, Movement Disorders Clinical Practice, (2025).https://doi.org/10.1002/mdc3.14324
    Crossref
  5. Neurosurgical and pharmacological management of dystonia, World Journal of Psychiatry, 14, 5, (624-634), (2024).https://doi.org/10.5498/wjp.v14.i5.624
    Crossref
  6. Subthalamic Nucleus Deep Brain Stimulation for Meige Syndrome: Long-Term Outcomes and Analysis of Prognostic Factors, Neurosurgery, (2024).https://doi.org/10.1227/neu.0000000000003228
    Crossref
  7. Deep brain stimulation for severe dystonia associated with Wilson disease: A prospective multicenter meta‐analysis of an N‐of‐1 trial, European Journal of Neurology, 32, 1, (2024).https://doi.org/10.1111/ene.16524
    Crossref
  8. Mapping dysfunctional circuits in the frontal cortex using deep brain stimulation, Nature Neuroscience, 27, 3, (573-586), (2024).https://doi.org/10.1038/s41593-024-01570-1
    Crossref
  9. A framework for translational therapy development in deep brain stimulation, npj Parkinson's Disease, 10, 1, (2024).https://doi.org/10.1038/s41531-024-00829-5
    Crossref
  10. Concerning neuromodulation as treatment of neurological and neuropsychiatric disorder: Insights gained from selective targeting of the subthalamic nucleus, para-subthalamic nucleus and zona incerta in rodents, Neuropharmacology, 256, (110003), (2024).https://doi.org/10.1016/j.neuropharm.2024.110003
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Figures

Tables

Media

Share

Share

Share article link

Share